DPP4 and hydrops fetalis: Enzan et al. found that DPP-4 inhibitors use was associated with better long-term outcomes and a lower incidence of cardiovascular death or HF hospitalization in patients with heart failure with preserved ejection fraction, but not in patients with heart failure with mildly reduced or reduced ejection fraction, and diabetes (Enzan et al., 2023).